Infectious Diseases and Therapy

metrics 2024

Innovating solutions for a healthier tomorrow.

Introduction

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

Metrics 2024

SCIMAGO Journal Rank1.35
Journal Impact Factor4.70
Journal Impact Factor (5 years)4.60
H-Index45
Journal IF Without Self4.70
Eigen Factor0.01
Normal Eigen Factor1.19
Influence1.33
Immediacy Index1.10
Cited Half Life2.70
Citing Half Life5.20
JCI0.93
Total Documents846
WOS Total Citations2892
SCIMAGO Total Citations6275
SCIMAGO SELF Citations159
Scopus Journal Rank1.35
Cites / Document (2 Years)4.52
Cites / Document (3 Years)4.37
Cites / Document (4 Years)4.17

Metrics History

Rank 2024

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 20/132
Percentile 85.20
Quartile Q1

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 32/132
Percentile 75.76
Quartile Q1

Quartile History

Similar Journals

LANCET INFECTIOUS DISEASES

Advancing the Frontiers of Infectious Disease Research
Publisher: ELSEVIER SCI LTDISSN: 1473-3099Frequency: 12 issues/year

LANCET INFECTIOUS DISEASES is a premier journal published by Elsevier Science Ltd, dedicated to disseminating high-quality research and comprehensive reviews in the field of infectious diseases. Since its inception in 2001, the journal has become a pivotal resource in the medical community, recognized for its rigorous peer-review process and impactful contributions to public health. With an impressive Scopus rank of #2 out of 344 in the category of Medicine - Infectious Diseases, it consistently ranks in the 99th percentile, highlighting its importance and influence in shaping clinical and epidemiological research. The journal's commitment to advancing knowledge in infectious diseases is underscored by its Q1 quartile designation in 2023, affirming its status as a leading academic outlet. Although not an open-access journal, LANCET INFECTIOUS DISEASES provides essential insights for researchers, healthcare professionals, and students, bridging the gap between cutting-edge research and practical application in an increasingly interconnected world.

Antibiotics-Basel

Advancing antibiotic research for a healthier tomorrow.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Connecting researchers to combat infectious threats.
Publisher: ELSEVIER SCI LTDISSN: 1201-9712Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

JOURNAL OF INFECTION AND CHEMOTHERAPY

Exploring Breakthroughs in Microbiology and Chemotherapy
Publisher: ELSEVIERISSN: 1341-321XFrequency: 6 issues/year

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi

Fostering collaboration for innovative solutions in clinical microbiology.
Publisher: BILIMSEL TIP YAYINEVIISSN: 1300-932XFrequency: 4 issues/year

Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi, published by BILIMSEL TIP YAYINEVI, is a leading journal dedicated to the field of infection diseases and clinical microbiology. With an ISSN of 1300-932X and an E-ISSN of 2602-2842, this journal has been an established Open Access platform since 1999, allowing researchers worldwide to access critical studies and advancements without barriers. The journal aims to disseminate high-quality research articles, reviews, and case studies that address emerging challenges in infection management and microbiological practices. By fostering a collaborative environment for professionals, researchers, and students alike, Flora Infeksiyon Hastaliklari ve Klinik Mikrobiyoloji Dergisi plays a vital role in advancing knowledge and practices within the microbiological and clinical spheres. Its commitment to open access ensures that invaluable resources are widely available, supporting the growth and development of innovation in the medical field.

CLINICAL INFECTIOUS DISEASES

Elevating standards in clinical microbiology.
Publisher: OXFORD UNIV PRESS INCISSN: 1058-4838Frequency: 24 issues/year

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

Brazilian Journal of Infectious Diseases

Elevating the discourse on infectious diseases globally.
Publisher: ELSEVIER BRAZILISSN: 1413-8670Frequency: 6 issues/year

The Brazilian Journal of Infectious Diseases, published by Elsevier Brazil, is a premier open-access journal dedicated to advancing research and clinical practice in the field of infectious diseases. Since its inception in 2001, this journal has been pivotal in disseminating innovative studies and reviews that inform healthcare professionals and researchers alike. With an impressive impact factor reflected by its ranking in the second quartile for Infectious Diseases and third quartile for Medical Microbiology in 2023, the journal ranks #127 out of 344 in medicine – infectious diseases and #61 out of 140 in medical microbiology, showcasing its reputable standing in the scientific community. The Brazilian Journal of Infectious Diseases invites contributions that highlight significant findings, novel methodologies, and critical reviews aimed at enhancing patient care and public health initiatives. With an international readership and a focus on pressing issues in infectious diseases, it serves as an essential platform for knowledge exchange and collaboration among scholars and practitioners across Brazil and beyond. By reinforcing the importance of open access to scientific literature, this journal not only promotes transparency but also enhances the global discourse surrounding infectious diseases.

Current Treatment Options in Infectious Diseases

Championing Evidence-Based Practices in Infectious Disease Management.
Publisher: SPRINGERNATUREISSN: Frequency: 4 issues/year

Current Treatment Options in Infectious Diseases, published by SpringerNature, is a pivotal peer-reviewed journal dedicated to advancing the field of infectious disease management and therapy. With a focus on the latest treatment modalities, this journal serves as a vital resource for researchers, healthcare professionals, and students striving to improve patient outcomes in infectious diseases. Although it is not an open-access journal, it offers valuable insights through carefully curated articles that emphasize evidence-based practices and innovative approaches in the treatment landscape. By fostering a cross-disciplinary dialogue, Current Treatment Options in Infectious Diseases aims to bridge the gap between research and clinical application, making it an essential platform for staying abreast of developments in this rapidly evolving field.

EMERGING INFECTIOUS DISEASES

Advancing the Frontlines of Infectious Disease Research
Publisher: CENTERS DISEASE CONTROL & PREVENTIONISSN: 1080-6040Frequency: 12 issues/year

Emerging Infectious Diseases, published by the Centers for Disease Control and Prevention, is a leading open-access journal that has been dedicated to the field of epidemiology, infectious diseases, and medical microbiology since its inception in 1995. With an impressive impact factor placing it in the Q1 quartile rankings for multiple categories including Epidemiology, Infectious Diseases, and Medical Microbiology, this journal serves as a vital resource for researchers, practitioners, and students dedicated to combating the challenges posed by emerging infectious diseases. The journal's distinguished Scopus ranks further highlight its global influence, ranking #10 in Epidemiology, #26 in Infectious Diseases, and #13 in Medical Microbiology, all within the top percentiles. Accessible and targeted, Emerging Infectious Diseases publishes seminal research and reviews that contribute to the understanding and management of infectious diseases, ensuring that critical insights reach a broad audience. The journal encourages contributions that advance the scientific community’s knowledge and responses to public health challenges.

Infectious Disease Reports

Leading the charge in infectious disease research and collaboration.
Publisher: MDPIISSN: Frequency: 6 issues/year

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.